Eli Lilly’s Potential Acquisition of AtaiBeckley
Eli Lilly (NYSE:LLY) is reported to be in advanced discussions to acquire AtaiBeckley, a developer of psychedelic‑based medicines, according to Bloomberg news citing people familiar with the matter. The talks suggest a transaction value that places AtaiBeckley at an estimated $2 billion, representing a premium to its current market valuation after the company’s shares more than doubled over the past year.
Lilly has been exploring opportunities in the psychedelic‑therapy space for some time. BMO Capital Markets, which rates Lilly “Outperform” with a $1,300 price target, noted that a successful acquisition would add a platform of rapid‑acting psychedelic therapies and broaden Lilly’s neuroscience portfolio into treatment‑resistant depression (TRD) and other difficult‑to‑treat psychiatric disorders. The brokerage highlighted that increasing regulatory support for psychedelic‑based mental‑health treatments presents a meaningful long‑term opportunity for Lilly.
AtaiBeckley’s lead candidate, BPL‑003, is a fast‑acting psychedelic nasal spray that has demonstrated encouraging results in mid‑stage clinical trials and has received the U.S. Food and Drug Administration’s Breakthrough Therapy designation. The company also has pipeline assets VLS‑01 targeting TRD and EMP‑01 aimed at social anxiety disorder, which could provide additional late‑stage neuropsychiatric options if the deal closes.
The interest in psychedelic medicines has accelerated following the commercial success of Johnson & Johnson’s Spravato and improving clinical trial data across the sector. If finalized, the transaction could give Lilly a differentiated late‑stage neuropsychiatric asset and expand its pipeline optionality.